A review updates the classification of chronic inflammatory enteropathies (CIEs) in dogs. Current classification divides CIEs into food-responsive (FREs), antibiotic-responsive (AREs), immunosuppressant-responsive (IREs), and non-responsive (NREs) categories based on treatment response. However, recent research challenges this classification, highlighting the role of the gut microbiota in CIE pathogenesis and the limitations of antibiotic use. The study proposes replacing AREs with microbiota-related modulation-responsive enteropathies (MrMREs), which encompass treatments targeting microbiota restoration, such as prebiotics, probiotics, and fecal microbiota transplantation. The classification is refined to include MrMREs, FREs, IREs, and NREs, with a focus on diet and microbiota modulation. The study emphasizes the importance of diet in modulating the gut microbiota and the need for further research to assess the effectiveness of microbiota-targeted therapies. The revised classification aims to improve the management of CIEs by incorporating recent advances in understanding the role of the gut microbiota in disease pathogenesis.A review updates the classification of chronic inflammatory enteropathies (CIEs) in dogs. Current classification divides CIEs into food-responsive (FREs), antibiotic-responsive (AREs), immunosuppressant-responsive (IREs), and non-responsive (NREs) categories based on treatment response. However, recent research challenges this classification, highlighting the role of the gut microbiota in CIE pathogenesis and the limitations of antibiotic use. The study proposes replacing AREs with microbiota-related modulation-responsive enteropathies (MrMREs), which encompass treatments targeting microbiota restoration, such as prebiotics, probiotics, and fecal microbiota transplantation. The classification is refined to include MrMREs, FREs, IREs, and NREs, with a focus on diet and microbiota modulation. The study emphasizes the importance of diet in modulating the gut microbiota and the need for further research to assess the effectiveness of microbiota-targeted therapies. The revised classification aims to improve the management of CIEs by incorporating recent advances in understanding the role of the gut microbiota in disease pathogenesis.